Publication date: Jul 20, 2026
This study aimed to investigate differences in the composition and functional characteristics of alveolar microbiota in patients with pulmonary tuberculosis (PTB) exhibiting differential therapeutic responses. Thirty-two patients with drug-sensitive PTB who had completed standard anti-tuberculosis therapy were enrolled and classified into good-response (n = 16) and poor-response (n = 16) groups. Bronchoalveolar lavage fluid (BALF) samples were collected and analysed using metagenomic sequencing to characterize microbial community and functional pathways. No significant differences were observed in α-diversity between the two groups; however, β-diversity analysis demonstrated moderate but significant in microbial community structure (ANOSIM, R = 0. 381, P
Open Access PDF
| Concepts | Keywords |
|---|---|
| Bronchoalveolar lavage fluid | |
| Metagenomics | |
| Pulmonary microbiome | |
| Pulmonary tuberculosis | |
| Therapeutic efficacy |
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | pulmonary tuberculosis |
| disease | MESH | tuberculosis |
| pathway | KEGG | Tuberculosis |
| drug | DRUGBANK | (S)-Des-Me-Ampa |
| pathway | REACTOME | Reproduction |
| disease | MESH | included |
| disease | MESH | Infectious Diseases |
| drug | DRUGBANK | Coenzyme M |
| pathway | KEGG | Peptidoglycan biosynthesis |
| pathway | KEGG | Glutathione metabolism |
| pathway | KEGG | Biofilm formation |
| pathway | REACTOME | Infectious disease |
| disease | MESH | relapse |
| drug | DRUGBANK | Isoniazid |
| drug | DRUGBANK | Rifampicin |
| drug | DRUGBANK | Pyrazinamide |
| drug | DRUGBANK | Ethambutol |
| drug | DRUGBANK | Levofloxacin |
| disease | MESH | plan |
| disease | MESH | AIDS |
| disease | MESH | mental illness |
| disease | MESH | epilepsy |
| disease | MESH | immune system diseases |
| disease | MESH | fungal infections |
| disease | MESH | cough |
| disease | MESH | fever |
| disease | MESH | hemoptysis |